Navigation Links
Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study

Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase... -- ITTIGEN and BERN, Switzerland, November 11, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study


ITTIGEN and BERN, Switzerland, November 11, 2010 /PRNewswire/ -- Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. Vaccination of the first study group has been completed and demonstrated that PEV7 is safe and well-tolerated in all subjects and elicits an immune response even at low doses.

"This is an important step for both PEV7 and Pevion as we aim for proof of concept in humans with our innovative approach to disease management using a state-of-the-art subunit vaccine," comments Evert Kueppers, CEO of Pevion. "The fact that in the first volunteers we see immunogenicity at low doses of the vaccine's subunit antigen is very encouraging. In addition, the excellent tolerability of our virosome-delivered vaccines is once more confirmed in a human trial."

"A vaccine has the potential to break new ground here: the prevention of recurrencies, that no drug can provide," says Prof. Jack Sobel, a world leading specialist in the field of recurrent VVC from the Department of Internal Medicine at Wayne State University, Detroit, USA. "An efficient vaccine would bring relief to millions of women who are severely impacted by this disease."

The ongoing PEV7 Phase I study is designed to assess the safety and immunogenicity of the vaccine candidate. Half of the volunteers will receive intramuscular injections, while the other half will receive capsules, administered intravaginally. In total, the study will enroll 48 healthy women of childbearing age. Pevion's announcement follows the review by an independent Data and Safety Monitoring Board (DSMB) of the results from the first study group that received the vaccine intramuscularly at a low dose.

"The DSMB has now recommended that the trial should proceed with the next study group. This is an important development milestone," adds Kueppers. "RVVC is a major problem, as sufferers have at least four acute attacks per year with a significant effect on quality of life, affecting not just their physical condition, but also their psychological state. It is clear that a well-tolerated and effective vaccine will serve an important unmet medical need. Cure rates of RVVC with existing drug therapy remain disappointing. Reliable long-term protection does not exist and there is no prophylactic treatment available."

About Pevion Biotech

Pevion Biotech is an independent Swiss vaccine company that develops next generation vaccines based on its clinically and commercially validated virosome technology. Its proprietary pipeline includes a clinical stage candidiasis vaccine and preclinical programmes in RSV and universal flu. A clinical stage malaria vaccine candidate has been outlicensed and the Company`s technology is being used for an HIV vaccine currently in human trials. The Company has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was founded in 2002 as an industrial spin-off of Bachem AG (SWX: BANB) and Berna Biotech, now Crucell, (SWX: CRX), and raised a total of CHF 45 million to date from its founders and investors, BZ Bank, Core Capital Partners and BB Biotech Ventures.

About Virosomes

Virosomes are the only regulatory and market-approved vaccine technology to fulfill carrier and adjuvant functions in one. Essentially, virosomes represent reconstituted empty influenza virus envelopes, devoid of the genetic material of the source virus. As such, virosomes do not replicate and are therefore an ideal combination of carrier plus adjuvant for almost any given antigen, including peptide or protein derived antigens. The technology allows the surface display and delivery of difficult antigens and thereby provides access to new indications and markets. Two virosome-based vaccines (Epaxal(R) and Inflexal(R) V, marketed by Crucell Switzerland AG) are licensed in over 40 countries, and more than 70 million doses of these vaccines have been commercially distributed, thereby providing a solid safety and efficacy track record.

Contact: Christian Spyr, PhD Head Clinical Development & Project Management Phone: +41-31-550-44-44 E-Mail:

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
3. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
4. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
5. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
6. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
7. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
8. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
9. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
10. Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
11. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... , Nov. 25, 2015 Endo International plc (NASDAQ: ... De Silva , President and CEO, will discuss corporate updates ... in New York on Wednesday, December ... . Click on Investor Relations, and then the link to ... the presentation,s start time to visit the site and download ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The ... perfect dish and pleasing the palates of attendees is of the utmost importance. ... to a seasonal get-together, give these recipes a try this holiday season. , ...
(Date:11/25/2015)... Nairobi (PRWEB) , ... November 26, 2015 , ... ... African Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, ... Nations Office in Nairobi (UNON) for the opening of the 5th African Network ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Smiles ... of TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of ... of the great success Botox® delivers to those suffering with discomfort, soreness, and pain ...
(Date:11/25/2015)... ... , ... “While riding the bus, I saw a passenger in a wheelchair ... to be a convenient and comfortable way to protect them from bad weather, so ... safely travel during cold or inclement weather. In doing so, it ensures that the ...
Breaking Medicine News(10 mins):